Loading...
By Larry Husten
Edited by Susan Sadoughi, MD
Two diabetes drugs — the dipeptidyl peptidase-4 inhibitors saxagliptin (Onglyza) and alogliptin (Nesina) — survived a meeting of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee on Tuesday. Rejecting recommendations from critics that the drugs should either be withdrawn or get new restrictions, the committee voted against any harsh measures and instead advised only that information from two neutral clinical trials be added to the drugs' labels.
The two trials were the first large cardiovascular outcomes trials of any diabetes drug. SAVOR-TIMI 53 studied saxagliptin, while EXAMINE studied alogliptin. Both trials were neutral, finding no evidence of cardiovascular benefit or harm with the drugs.
The committee voted 13-1-1 that saxagliptin had an acceptable cardiovascular risk profile, while alogliptin sailed 16-0 through the committee on the cardiovascular risk profile question.
But the drugs aren't completely out of danger. A consistent signal for heart failure complications — which were not directly studied in SAVOR and EXAMINE — has not been easy to dismiss. Panel members called on the FDA to get companies to study the heart failure question more closely.
Comment
LINK(S):
FDA briefing documents (Free)
Background: NEJM Journal Watch Cardiology coverage of EXAMINE and SAVOR-TIMI 53 (Free)
Background: Physician's First Watch coverage of saxagliptin and heart failure (Free)